Insider Transactions and Holdings
-
Entity Type
-
Individual
-
Role
-
President and CEO, Director
-
Stock Symbol
-
ATHA on Nasdaq
Mark James Litton - trading volume in the past year for Athira Pharma, Inc.
Holdings reported by Mark James Litton for Athira Pharma, Inc.
Class |
Num Shares |
Value |
Price $ |
Transaction Date |
Ownership |
Underlying Class |
Underlying Amount |
Common Stock |
243K |
$136K |
$0.56 |
Jan 2, 2025 |
Direct |
|
|
Restricted Stock Units |
217K |
$122K |
$0.56 |
Dec 31, 2024 |
Direct |
Common Stock |
|
Common Stock |
6.56K |
$3.69K |
$0.56 |
Dec 31, 2024 |
By Irrevocable Trust of OSL |
|
|
Common Stock |
6.56K |
$3.69K |
$0.56 |
Dec 31, 2024 |
By Irrevocable Trust of SWL |
|
|
Common Stock |
6.56K |
$3.69K |
$0.56 |
Dec 31, 2024 |
By Irrevocable Trust of WGL |
|
|
Stock Option (Right to Buy) |
325K |
|
|
Oct 3, 2024 |
Direct |
Common Stock |
|
Transactions reported by Mark James Litton for Athira Pharma, Inc.
Sym |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares After |
Date |
Ownership |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.